// App-Quantinova.ai

: Efficacy of Systemic Therapies for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL): A Systematic Literature Review (SLR)

Researchers

Presenter

  • Emmanuel Bachy

Principal Investigators

  • Christopher P. Fox

  • Luca Arcaini

  • Francisco J. Hernandez-Ilizaliturri

  • Susannah Howlett

  • Sonya J. Snedecor

  • Jacob Franek

  • Omer Zaidi

  • Ashley Tabah

Medical Centers

  • Department of Nuclear Medicine, Hospices Civils de Lyon, CHU Lyon Sud, University Claude Bernard Lyon 1, Pierre Benite, France

  • Universite Claude Bernard Lyon , EPHE, Lyon, France

  • Nottingham University City Hospital NHS Trust, Nottingham, United Kingdom

  • Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Celgene Corporation, Summit, NJ

  • Pharmerit International, Bethesda, MD

  • Pharmerit International, Boston, MA

Locations

  • France

  • United Kingdom

  • Italy

  • United States

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Bendamustine

  • chlorambucil

  • Lenalidomide

  • Vincristine

  • Doxorubicin

  • Idelalisib

  • Prednisone

  • Copanlisib

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Observational

  • Multinational

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved